Tag: Minghui Pharmaceutical

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO...

MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye diseaseAt 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsMinghui Pharmaceutical

Futurionex Conclui Atualização de Proteção de Ativos dos Clientes e Deve Enviar Pedido de Licença MiCA no T3 de 2026

Brian Ferdinand Highlights the Importance of Strategic Thinking in Today’s Investment Landscape

Scituate School Department & Johnston Public Schools Select Zum to Modernize Student Mobility

Tag: Minghui Pharmaceutical

Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us